Essex Bio-Technology

What Essex Bio-Technology does

Essex Bio-Technology Limited is a Hong Kong-listed biopharmaceutical company (stock code 01061.HK) that develops, manufactures, and commercializes genetically engineered therapeutic fibroblast growth factors, principally recombinant bovine basic fibroblast growth factor (rb-bFGF), for ophthalmology, dermatology, and wound healing indications. Its core portfolio centers on the Beifushu, Beifuji, and Beifuxin product series, supplemented by preservative-free single-dose ophthalmic formulations and the recently approved multi-dose Diquafosol Sodium Eye Drops. The company industrialized bFGF production via proprietary E. coli fermentation and holds 121 patents including 91 invention patents, supported by R&D centers in Zhuhai, Singapore, Boston, and London.

The company sells primarily through a direct sales network of 47 regional offices and approximately 1,300 sales staff covering 14,600+ hospitals and 2,600+ pharmacies across China, generating approximately 60% market share in China's ophthalmology regenerative drugs and 40% in surgical wound repair. Revenue for FY2025 reached HK$1,813.8 million (+8.6% year over year) with HK$318.1 million in net profit, and the flagship Beifushu and Beifuji series contributed 83.5% of turnover. The pipeline includes Bevacizumab EB12-20145P (HLX04-O) for wet AMD (BLA accepted by NMPA in 2025), SkQ1 for dry eye, and adjacencies in dental (Carisolv via the acquired Wuhan Adv. Dental) and healthcare services (UNO Clinic, UNO e-Clinic, UNO Technologies).

Essex has pursued an "Enrichment Programme" since 2015, executing strategic equity investments in MeiraGTx, Antikor Biopharma, Humacyte, Abpro, AC Immune, and X-ZELL, and signing co-development and licensing agreements with Henlius (Bevacizumab), Mitotech (SkQ1), Osteopore (Singapore dental distribution), Gunze (PELNAC dressing), and Kenvue (OTC consumer health in China, December 2025). The 2025 Singapore launch of Beifushu via the Special Access Route marked the company's first overseas commercial entry, with Phase III trials ongoing in the US, EU, and Australia.

Name

Essex Bio-Technology

Legal name

Essex Bio-Technology Limited

Website

https://essexbio.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Essex Bio-Technology is a Hong Kong-listed biopharmaceutical company that develops, manufactures, and commercializes recombinant bovine basic fibroblast growth factor (rb-bFGF) therapies and other ophthalmology, dermatology, and wound healing biologics, distributed through 47 regional offices to 14,600+ hospitals across China.

Ownership category

akta.pro rank

Product category

Ophthalmic Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Dermatology Specialty Pharmaceuticals (HLAIACAL), Anti-VEGF Biosimilars (HLAIAFAG)

Keywords

• Biopharmaceutical products
• Ophthalmic pharmaceuticals
• Wound healing therapeutics
• Recombinant growth factors
• Preservative-free eye drops

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Technology or R&D, Personnel, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue from sale of biopharmaceutical products including Beifushu (eye drops, eye gel), Beifuji (lyophilized powder), Beifuxin (gel), and other eye drops and pharmaceutical products through hospital and pharmacy network.
2. Flagship Product Series: Beifushu and Beifuji product series contributed 83.5% of total turnover in 2025.
3. Distribution and Sales Services: Sales and marketing services for third-party products including Shilishun (Iodized Lecithin Capsules), Yi Xue An Granules, and exclusive distribution of Osteopore dental products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Essex Bio-Technology develops, manufactures and commercialises genetically engineered therapeutic fibroblast growth factors (FGF), with six flagship biologics approved for ophthalmology, dermatology and wound healing indications since 1998. Its portfolio centres on recombinant bovine basic fibroblast growth factor (rb-bFGF) products including Beifushu eye drops/gel, Beifuji lyophilized powder, Beifuxin gel, and a growing line of preservative-free unit-dose ophthalmic formulations. Products are sold primarily to more than 14,600 hospitals across China via 47 directly managed regional sales offices, with emerging international expansion through Singapore and pipeline biologics for wet AMD.

Product overview

Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic fibroblast growth factors (FGF). The portfolio includes six flagship biologics approved since 1998: Beifushu (rb-bFGF eye drops), Beifuji (rb-bFGF lyophilized powder), and Beifuxin (rb-bFGF gel) for Ophthalmology and Wound Healing/Dermatology, along with newer formulations including preservative-free single-dose eye drops, Diquafosol Sodium Eye Drops, and Sodium Hyaluronate Eye Drops. The Company also has pipeline products including Bevacizumab EB12-20145P (HLX04-O) for wet AMD and SkQ1 for dry eye disease. Additionally, the HealthTech segment includes UNO Clinic (physical medical clinics), UNO e-Clinic (online healthcare platform), and UNO Technologies (clinic management and EMR systems). Products are available in more than 14,600 hospitals across China.

Differentiator

Problem solved

Functional benefit

Brands

• Beifushu: Recombinant bovine basic fibroblast growth factor (rb-bFGF) eye drops and eye gel for ophthalmology
• Beifuji
• Beifuxin
• UNO Clinic
• UNO e-Clinic
• UNO Technologies

Products and services

• Beifushu (贝复舒) rb-bFGF Eye Drops and Eye Gel Recombinant bovine basic fibroblast growth factor (rb-bFGF) eye drops and eye gel for ophthalmology indications including ocular surface repair, corneal damage, corneal surgery, and dry eye disease. Recognized as a well-known trademark in Guangdong Province.
• Beifuji (贝复济) rb-bFGF Lyophilized Powder

Quantifiable outcome

• rb-bFGF production cost reduced from billions per gram to ~1 million RMB per kg through E. coli fermentation technology
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core, major, strategic and acquisition.

• KenvuecoreStrategic or Co-development Partner · 17 December 2025Strategic cooperation for consumer health products including Motrin, Tylenol, and Rhinocort brands in China market.
• Suzhou Industrial Park Investment Promotion & Operation Co., Ltd. (SIPIPO)coreStrategic or Co-development Partner · 21 November 2025MOU signed for cross-border life sciences accelerator to support international innovation and market access.
• BiosparccoreStrategic or Co-development Partner · 21 November 2025MOU for international innovation accelerator collaboration with Suzhou Industrial Park.
• OsteoporemajorChannel Partner/ Reseller/ Distributor · 14 April 2023Exclusive distribution agreement for oral maxillofacial products in Singapore market.
• Gunze ShenzhenmajorChannel Partner/ Reseller/ Distributor · 11 April 2023Exclusive agency agreement for PELNAC absorbable dressing in mainland China.
• Henlius (Shanghai Henlius Biotech)coreStrategic or Co-development Partner · 22 February 2023Global co-development and exclusive license agreement for Bevacizumab (HLX04-O) for treatment of age-related macular degeneration. Amended agreement for expanded global development rights.
• MitotechcoreStrategic or Co-development Partner · 13 October 2022Secured exclusive global rights and interests of SkQ1 in ophthalmology field for dry eye disease treatment.
• Kelun-BiotechmajorOEM/ Whitelabel/ Licensing Partner · 10 August 2020Global out-licence agreement for technology transfer and commercialization rights.
• Antikor BiopharmastrategicStrategic or Co-development Partner · 19 July 2019Strategic alliance in fragment drug conjugates (FDC) for cancer treatment. Subscription for shares up to 40.12% of enlarged capital.
• Wuhan Adv. Dental Co., Ltd.acquisitionOthers · 1 April 2019Acquisition of 100% equity interest. Major product Carisolv for minimally invasive dental caries treatment.
• AbprostrategicStrategic or Co-development Partner · 28 February 2019Partnership with Nanjingtech (NJCTTQ) for development of multiple novel bispecific antibodies using Abpro's DiversImmune platform. Abpro eligible for up to US$4 billion including US$60 million R&D funding.
• DB TherapeuticsstrategicStrategic or Co-development Partner · 30 October 2018Convertible notes purchase agreement and license agreement for non-melanoma skin cancer treatment.
• MitotechcoreStrategic or Co-development Partner · 18 July 2018Global co-development agreement for SkQ1 Phase 3 clinical trial in US FDA for dry eye disease. Essex invested up to US$16.52 million for first phase, with rights to second phase investment.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zhaoke Ophthalmology Limited: Hong Kong-listed (6622.HK) Chinese ophthalmology pharmaceutical company with a comparable focus on ophthalmic therapeutics in China. Similar in size and channel strategy, with products covering dry eye, myopia, and retinal diseases — directly comparable to Essex's ophthalmology franchise.
• Shanghai Henlius Biotech (Henlius): Hong Kong-listed (2696.HK) Chinese biopharma and Essex's direct co-development partner for Bevacizumab HLX04-O. Comparable as a Chinese biopharma developing biologics and biosimilars with global ambitions, and as a co-developer it shares the same HLX04-O value chain risk and reward.
• Chengdu Kanghong Pharmaceutical Group: Chinese ophthalmology pharmaceutical company that developed Conbercept (Langmu), an anti-VEGF therapy approved in China for wet AMD. Direct competitor in the ophthalmology anti-VEGF space where Essex's HLX04-O will compete, with overlapping regulatory and commercial pathways.

Emerging players

• Sciwind Biosciences: Chinese biopharma developing ophthalmology biologics and biosimilars including anti-VEGF candidates. Comparable as a domestic peer pursuing ophthalmology biosimilars in China, with potential overlap in target indications such as wet AMD.
• Samsung Bioepis: Korean biosimilar developer with approved biosimilars including in ophthalmology (SB15, ranibizumab biosimilar referencing Lucentis). Comparable as a competitor developing anti-VEGF biosimilars that Essex's HLX04-O will compete against in global markets.
• Bio-Thera Solutions: Chinese biosimilar developer with multiple ophthalmology biosimilars in clinical development (including BAT1706, bevacizumab biosimilar). Comparable as a direct competitor in the Chinese anti-VEGF biosimilar space and as a fellow Chinese biopharma pursuing global biosimilar approvals.

Broad incumbents

• Innovent Biologics: Hong Kong-listed (1801.HK) Chinese biopharmaceutical company with a much broader oncology and immunology pipeline. Comparable as a HK-listed Chinese biopharma with biologics manufacturing capabilities and ambitions for global product launches.
• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed (512.HK) Chinese pharmaceutical company with a meaningful ophthalmology portfolio alongside cardiovascular and respiratory products. Comparable as a larger, more diversified Chinese specialty pharma with overlapping ophthalmology positioning.
• Santen Pharmaceutical: Japan-based global ophthalmology pharmaceutical company with a broad prescription ophthalmology portfolio across dry eye, glaucoma, and retinal diseases. Comparable as an established ophthalmology pure-play providing a global benchmark for product strategy, regulatory approach, and commercial model in the specialty.

Regional players

• Lee's Pharmaceutical Holdings: Hong Kong-listed (950.HK) specialty pharmaceutical company focused on therapeutics in China and Asia. Comparable as a smaller HK-listed specialty pharma with a similar model of licensing/in-licensing specialty products and operating a hospital-focused sales channel in China.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Essex Bio-Technology